Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of PCV10 and PCV13: Findings from the PSERENADE project

PSERENADE Team, Julia C. Bennett, Marissa K. Hetrich, Maria Garcia Quesada, Jenna N. Sinkevitch, Maria Deloria Knoll, Daniel R. Feikin, Scott L. Zeger, Eunice W. Kagucia, Adam L. Cohen, Krow Ampofo, Maria Cristina C. Brandileone, Dana Bruden, Romina Camilli, Jesús Castilla, Guanhao Chan, Heather Cook, Jennifer E. Cornick, Ron Dagan, Tine DalbyKostas Danis, Sara de Miguel, Philippe De Wals, Stefanie Desmet, Theano Georgakopoulou, Charlotte Gilkison, Marta Grgic‐vitek, Laura L. Hammitt, Markus Hilty, Pak Leung Ho, Sanjay Jayasinghe, James D. Kellner, Jackie Kleynhans, Mirjam J. Knol, Jana Kozakova, Karl G. Kristinsson, Shamez N. Ladhani, Laura Macdonald, Grant A. Mackenzie, Lucia Mad’arová, Allison McGeer, Jolita Mereckiene, Eva Morfeldt, Tuya Mungun, Carmen Muñoz‐almagro, J Pekka Nuorti, Metka Paragi, Tamara Pilishvili, Rodrigo Puentes, Samir K. Saha, Aalisha Sahu Khan

Tutkimustuotos: ArtikkeliScientificvertaisarvioitu

2 Sitaatiot (Scopus)

Abstrakti

Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococ-cal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) con-taining ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERE‐ NADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) compar-ing the pre‐PCV10/13 period to each post‐PCV10/13 year by site using a Bayesian multi‐level, mixed-effects Poisson regression and all‐site IRRs using a linear mixed‐effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all‐site IRR was 0.05 (95% credibility interval 0.04–0.06) for all ages, 0.05 (0.04–0.05) for <5 years of age, 0.08 (0.06–0.09) for 5–17 years, 0.06 (0.05–0.08) for 18–49 years, 0.06 (0.05–0.07) for 50–64 years, and 0.05 (0.04–0.06) for ≥65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3+0 schedule constrains generalizability and data from these settings are needed.

AlkuperäiskieliEnglanti
Artikkeli696
JulkaisuMicroorganisms
Vuosikerta9
Numero4
DOI - pysyväislinkit
TilaJulkaistu - 2021
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Microbiology
  • Virology
  • Microbiology (medical)

Sormenjälki

Sukella tutkimusaiheisiin 'Changes in invasive pneumococcal disease caused by streptococcus pneumoniae serotype 1 following introduction of PCV10 and PCV13: Findings from the PSERENADE project'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä